

FLASH2: Accelerating recruitment for novel asthma therapy, across 14 specialist study sites.

About the Study


FLASH2 investigated the safety and efficacy of Atuliflapon, a novel investigational medication for the treatment of moderate to severe uncontrolled asthma in adults.

The study sought male and female adults participants aged 18–80, with an asthma diagnosis confirmed at least 12 months prior to screening.

With an initial target of 33 highly-qualified patient referrals, uMed engaged over 70k patients across 14 study sites through its clinically-validated 'Recruit' EHR identification and screening process, ultimately referring 115 to trial.



Key Outcomes



88,813

Patients identified as eligible through EHR data



72,612

Patients engaged in outreach



852

Patients consented for uMed screening



115

Patients referred to trial, across 14 study sites

Smarter screening, stronger referrals.

FLASH2 demonstrated uMed Recruit's ability to identify and mobilise large patient populations rapidly and at scale.

The initial target of 33 highly-qualified referrals was exceeded by almost 250%, with 115 patients ultimately referred to trial.

uMed's approach to recruitment combines clinically-validated EHR identification, multi-modal outreach, and a dedicated patient screening and support function — allowing sites to focus on clinical delivery while uMed manages cohort operations.



Robust patient recruitment infrastructure repositions referral targets as a floor, rather than a ceiling. With clinically-validated access to large patient populations, finding the right patients is no longer a limiting factor in trial success.

uMed's unique capabilities	For Sites	For Sponsors
Automated patient identification via EHR records	Low burden. GPs confirm patient eligibility with 1-click	Rapid, targeted reach of a large volume of eligible patients. Significantly reduced study delivery timelines.
Multi-modal approach to contacting & consenting patients via SMS, email, and phone calls	Low burden. All contact & consent handled by uMed.	Consent rate of 11% (vs 2-3% in similar paediatric studies)
Three-stage screening (EHR → engagement → nurse-led)	Only protocol-ready patients referred	Fewer screen failures, lower site costs



To understand how uMed can deliver the custom data and insights required to accelerate your research, contact us at hello@umed.io